TY - JOUR
T1 - Kidney transplant recipient attitudes toward a sars-cov-2 vaccine
AU - Ou, Michael T.
AU - Boyarsky, Brian J.
AU - Zeiser, Laura B.
AU - Chiang, Teresa Po Yu
AU - Ruddy, Jake
AU - Rasmussen, Sarah E.Van Pilsum
AU - Martin, Jennifer
AU - Russell, Jennifer St Clair
AU - Durand, Christine M.
AU - Avery, Robin K.
AU - Werbel, William A.
AU - Cooper, Matthew
AU - Massie, Allan B.
AU - Segev, Dorry L.
AU - Garonzik-Wang, Jacqueline M.
N1 - Funding Information:
Received 2 March 2021. Revision received 25 March 2021. Accepted 8 April 2021. 1Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD. 2National Kidney Foundation, New York, NY. 3Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. 4Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD. 5Medstar Georgetown Transplant Institute, Washington, DC. 6Scientific Registry of Transplant Recipients, Minneapolis, MN. The authors declare no funding or conflicts of interest. This research was made possible with generous support of the Ben-Dov family. This work was supported by grant number F32DK124941 (Boyarsky), K01DK101677 (Massie), and K23DK115908 (Garonzik-Wang) from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), GSAN201C0WW (Werbel) from Am J Transplant, and K24AI144954 (Segev) from the National Institute of Allergy and Infectious Diseases (NIAID). The analyses described here are the responsibility of the authors alone and do not necessarily reflect the views or policies of the Department of Health and
Publisher Copyright:
Copyright © 2021 The Author(s).
PY - 2021/4/2
Y1 - 2021/4/2
N2 - Background. A widely accepted severe acute respiratory syndrome 2 (SARS-CoV-2) vaccine could protect vulnerable populations, but the willingness of solid organ transplant recipients (SOTRs) to accept a potential vaccine remains unknown. Methods. We conducted a national survey of 1308 SOTRs and 1617 non-SOTRs between November 11 and December 2, 2020 through the network of the National Kidney Foundation. Results. Respondents were largely White (73.2%), female (61.1%), and college graduates (56.2%). Among SOTRs, half (49.5%) were unsure or would be unwilling to receive a SARS-CoV-2 vaccine once available. Major concerns included potential side effects (85.2%), lack of rigor in the testing and development process (69.7%), and fear of incompatibility with organ transplants (75.4%). Even after the announcement of the high efficacy of the mRNA-1273 vaccine (Moderna Inc.) at the time of survey distribution, likeliness to receive a vaccine only slightly increased (53.5% before announcement versus 57.8% after the announcement). However, 86.8% of SOTRs would accept a vaccine if recommended by a transplant provider. Conclusions. SOTRs reported skepticism in receiving a potential SARS-CoV-2 vaccine, even after announcements of high vaccine efficacy. Reassuringly, transplant providers may be the defining influence in vaccine acceptance and will likely have a critical role to play in promoting vaccine adherence.
AB - Background. A widely accepted severe acute respiratory syndrome 2 (SARS-CoV-2) vaccine could protect vulnerable populations, but the willingness of solid organ transplant recipients (SOTRs) to accept a potential vaccine remains unknown. Methods. We conducted a national survey of 1308 SOTRs and 1617 non-SOTRs between November 11 and December 2, 2020 through the network of the National Kidney Foundation. Results. Respondents were largely White (73.2%), female (61.1%), and college graduates (56.2%). Among SOTRs, half (49.5%) were unsure or would be unwilling to receive a SARS-CoV-2 vaccine once available. Major concerns included potential side effects (85.2%), lack of rigor in the testing and development process (69.7%), and fear of incompatibility with organ transplants (75.4%). Even after the announcement of the high efficacy of the mRNA-1273 vaccine (Moderna Inc.) at the time of survey distribution, likeliness to receive a vaccine only slightly increased (53.5% before announcement versus 57.8% after the announcement). However, 86.8% of SOTRs would accept a vaccine if recommended by a transplant provider. Conclusions. SOTRs reported skepticism in receiving a potential SARS-CoV-2 vaccine, even after announcements of high vaccine efficacy. Reassuringly, transplant providers may be the defining influence in vaccine acceptance and will likely have a critical role to play in promoting vaccine adherence.
UR - http://www.scopus.com/inward/record.url?scp=85109520126&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85109520126&partnerID=8YFLogxK
U2 - 10.1097/TXD.0000000000001171
DO - 10.1097/TXD.0000000000001171
M3 - Article
C2 - 34131585
AN - SCOPUS:85109520126
SN - 2373-8731
VL - 7
JO - Transplantation Direct
JF - Transplantation Direct
IS - 7
M1 - e713
ER -